# A Study of IPM514 in Patients With Esophageal Squamous Cell Carcinoma.

> **NCT07203898** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Beijing Immupeutics Medicine Technology Limited** · enrollment: 36 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** IPM514

## Key facts

- **NCT ID:** NCT07203898
- **Lead sponsor:** Beijing Immupeutics Medicine Technology Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07203898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07203898, "A Study of IPM514 in Patients With Esophageal Squamous Cell Carcinoma.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07203898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*